ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 2463 for:    depression AND Major Depression AND major | "Depression"

Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03230682
Recruitment Status : Recruiting
First Posted : July 26, 2017
Last Update Posted : July 26, 2017
Sponsor:
Information provided by (Responsible Party):
Jianhui Fu, Huashan Hospital

Brief Summary:
Early improvemrnt, decreased 20% in the 17 items of Hamilton Depression Rating Scale (HAMD-17) at the second week of the treatment of major depression disorder (MDD), can arguably predict the remission at the 12th week. Our observation study including 80 MDD patients will access resting-state function MRI to finding factors which infuencing early improvemrnt, respone and remission of antidepressants.

Condition or disease Intervention/treatment
Major Depressive Disorder Drug: antidepressant

Study Type : Observational [Patient Registry]
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Months
Official Title: Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder
Estimated Study Start Date : July 25, 2017
Estimated Primary Completion Date : June 11, 2018
Estimated Study Completion Date : July 11, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants

Group/Cohort Intervention/treatment
major depressive disorder Drug: antidepressant
regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)




Primary Outcome Measures :
  1. Early improvement [ Time Frame: the second week of treatment ]
    obtain 20% decrease of HAMD-17


Secondary Outcome Measures :
  1. Response [ Time Frame: the 12th week of treatment ]
    obtain 50% decrease of HAMD-17



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The han nationality who living in Shanghai, Zhejiang Province and Jiangsu Province
Criteria

Inclusion Criteria:

  • right-handed; HAMD-17 more than 17; diagnosed with MDD by the Structured Clinical Interview for DSM-IV

Exclusion Criteria:

  • patients diagnosed with other condition in DSM-IV Axis I; pregnency; Thyroid disease; Heart Disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03230682


Contacts
Contact: Shi Shenxun, PhD 13816203171 shishenxun@163.com

Locations
China, Shanghai
Dept. of Neurology, Huashan Hospital, Fudan University Recruiting
Shanghai, Shanghai, China, 200040
Contact: Jie Tang    +8618818210880    tan11711@hotmail.com   
Sponsors and Collaborators
Huashan Hospital

Publications of Results:
Other Publications:
Responsible Party: Jianhui Fu, Department of Neurology, Huashan Hospital, Huashan Hospital
ClinicalTrials.gov Identifier: NCT03230682     History of Changes
Other Study ID Numbers: KY2017-01
First Posted: July 26, 2017    Key Record Dates
Last Update Posted: July 26, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jianhui Fu, Huashan Hospital:
early improvement
antidepressants
major depression diorder
resting-state fMRI

Additional relevant MeSH terms:
Disease
Depression
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Behavioral Symptoms
Mood Disorders
Mental Disorders
Antidepressive Agents
Psychotropic Drugs